September 1, 2024
PRESS RELEASE

Our collaboration with MSKCC: Advancing breast cancer care together

This month, we proudly signed a collaboration agreement with Memorial Sloan Kettering Cancer Center (MSKCC) in New York, one of the world’s leading cancer institutions. Founded in 1884, MSKCC is renowned for its comprehensive cancer care, cutting-edge research, and educational programs. With a dedicated team of over 1,200 physicians, MSKCC treats thousands of patients annually, addressing nearly 400 types of cancer. Their commitment to personalized medicine and innovative treatments has established them as pioneers in oncology.

This partnership marks a significant milestone for us at MultiplexDX. Together with MSKCC’s oncologists, we will work on further clinical validation of our Multiplex8+ test for breast cancer patients. This collaboration grants us access to invaluable patient samples and clinical data, allowing our test to be utilized for selected patients at MSKCC to help identify the most effective treatments.

We are immensely proud to represent Slovakia on the global stage, demonstrating the value of our innovative solutions in the fight against cancer.

More information about MSKCC

About MultiplexDX

MultiplexDX is one of the most innovative biotech corporations, created to bring its revolutionary technologies to the market of personalized molecular diagnostics. The company has representation in both U.S. and European markets. The collaborators of MultiplexDX are from the world’s most prestigious scientific organizations including the National Cancer Institute, Rockefeller University, Albert Einstein University, Vanderbilt University, Cornell University, Queens University (Canada), Hebrew University of Jerusalem (Israel), and the Max Delbrück Center for Molecular Medicine (Germany).

MultiplexDX IP-based and innovative platform merges histopathology methods, biomarker quantification, visualization and gene expression with a single-cell resolution by combining MDX proprietary visual and sequencing technologies into one diagnostic test. This cross-validation approach eliminates diagnostic errors and creates 100% precise cancer profiling for each patient which allows clinicians to suggest specific, personalized cancer treatment.

Find out more about MultiplexDX on Corporate website, Facebook, LinkedIn, Twitter

Other latest

MultiplexDX News